Tables

1.1 Trends in merger remedies 4
1.2 Distribution of mergers and remedies across broad sectors 6
1.2(a) The case study industries 7
3.1 EC remedy types, 1996–2000 38
3.2 An alternative classification of EC remedy types, 1991–2005 38
3.3 Remedy by type of competition concern 39
3.4 Remedies by theory of harm 39
5.1 NACE 21 pulp, paper and paper products 75
5.2 Merger interventions classified by markets in which remedies imposed 76
5.3 Paper production and consumption by grade, 2001: CEPI classification 77
5.4 Some indicators of structure and performance 79
5.5 Geographical distribution of production by broad product category, leading countries’ shares 80
5.6 European firms in the world’s top 100 81
5.7 Capacity utilization in the graphic paper sector 84
5.8 Main mergers/JV proposals by the largest firms 85
5.9 Leading market shares and concentration in the graphic paper sector 87
5.10 Leading market shares and concentration in the tissues sector 89
5.11 Leading ten market shares in packaging 90
6.1 Dimensions of market, 1994 95
6.2 Estimates of price elasticities for toilet tissue 96
6.3 Number and size distribution of sellers 98
6.4 Advertising spends, 1994 (£000) 100
6.5 Derivation of relative prices in the three segments 103
6.6 Imputing the own-price elasticities 104
6.7 The required comparisons 107
6.8 Theoretical mark-ups pre- and post-merger 109
6.9 Simulated price increases according to diversion ratio 111
6.10 Imputed market shares for individual private labels 112
6.11 Simulation results for toilet tissues 113
<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.12</td>
<td>Simulation results for kitchen towels and facials</td>
<td>114</td>
</tr>
<tr>
<td>6.13</td>
<td>Actual price outcomes</td>
<td>115</td>
</tr>
<tr>
<td>6.14</td>
<td>Actual market shares</td>
<td>117</td>
</tr>
<tr>
<td>6.15</td>
<td>Market structure in 2000 (by volume)</td>
<td>120</td>
</tr>
<tr>
<td>6.16</td>
<td>The required comparisons</td>
<td>124</td>
</tr>
<tr>
<td>6.17</td>
<td>Simulated price increases</td>
<td>130</td>
</tr>
<tr>
<td>7.1</td>
<td>NACE 24.4 manufacture of pharmaceuticals, medicinal chemicals and botanical products</td>
<td>135</td>
</tr>
<tr>
<td>7.1 (a)</td>
<td>Anatomical therapeutic chemical classification system</td>
<td>136</td>
</tr>
<tr>
<td>7.1 (b)</td>
<td>Typical drug groups as used in the industry (for example, company reports)</td>
<td>136</td>
</tr>
<tr>
<td>7.2</td>
<td>Merger interventions classified by drug type for which remedies were imposed</td>
<td>137</td>
</tr>
<tr>
<td>7.3</td>
<td>Size of the world’s market in pharmaceuticals, 1985–2002</td>
<td>140</td>
</tr>
<tr>
<td>7.3 (a)</td>
<td>The member states, the USA and Japan</td>
<td>141</td>
</tr>
<tr>
<td>7.4</td>
<td>The world’s 50 largest pharmaceutical firms, 2002</td>
<td>142</td>
</tr>
<tr>
<td>7.5</td>
<td>The world’s top selling drugs, 2002</td>
<td>144</td>
</tr>
<tr>
<td>7.6</td>
<td>Main mergers by the largest firms</td>
<td>145</td>
</tr>
<tr>
<td>7.7</td>
<td>The impact of mega-mergers on Europe’s top ten in 2002</td>
<td>147</td>
</tr>
<tr>
<td>7.8</td>
<td>US FDA approval timescale</td>
<td>152</td>
</tr>
<tr>
<td>7.9</td>
<td>Regulatory success rates for pipeline products</td>
<td>153</td>
</tr>
<tr>
<td>7.10</td>
<td>Mean number of competitor products per molecule by country</td>
<td>164</td>
</tr>
<tr>
<td>7.11</td>
<td>Importance of elasticities – market share analysis compared with basic simulation (using PCAIDS)</td>
<td>173</td>
</tr>
<tr>
<td>8.1</td>
<td>Pharmaceuticals mergers, markets and simulations</td>
<td>180</td>
</tr>
<tr>
<td>8.2</td>
<td>Market shares for selected CCR markets</td>
<td>185</td>
</tr>
<tr>
<td>8.3</td>
<td>Simulated effect of allowing merger of BM/Roche CCS businesses</td>
<td>187</td>
</tr>
<tr>
<td>8.4</td>
<td>Market shares in immediate-release analgesics in Sweden</td>
<td>192</td>
</tr>
<tr>
<td>8.5</td>
<td>Simulated effect of allowing merger and accepted remedies for PU/Monsanto in immediate-release analgesics in Sweden</td>
<td>193</td>
</tr>
<tr>
<td>8.6</td>
<td>Commercial and scientific names of main products</td>
<td>209</td>
</tr>
<tr>
<td>8.7</td>
<td>AstraZeneca: chirocaine simulations</td>
<td>212</td>
</tr>
<tr>
<td>8.8</td>
<td>Market shares in anti-virals (excluding HIV)</td>
<td>221</td>
</tr>
<tr>
<td>8.9</td>
<td>Simulated effects of unremedied GWSB merger in anti-virals (excluding HIV)</td>
<td>222</td>
</tr>
<tr>
<td>8.10</td>
<td>Market shares in topical anti-virals</td>
<td>223</td>
</tr>
<tr>
<td>8.11</td>
<td>Simulated effects of unremedied GWSB merger in topical anti-virals</td>
<td>224</td>
</tr>
<tr>
<td>9.1</td>
<td>Summary assessment of case study mergers and remedies</td>
<td>241</td>
</tr>
</tbody>
</table>